SAN DIEGO, Sept. 6, 2016 /PRNewswire/ -- ResMed (NYSE: RMD)
welcomed positive results from a multicenter, randomized controlled
trial known as HOT-HMV. The study was presented today during the
2016 European Respiratory Society International Congress, in
London.
The HOT-HMV trial studied COPD patients who were hypercapnic,
that is, had high carbon dioxide levels in their blood, and who
were hospitalized after their COPD worsened. The study assessed
whether adding home non-invasive ventilation to home oxygen therapy
could improve the length of time these patients went without dying
or being re-admitted to the hospital.
COPD is a collection of lung diseases including chronic
bronchitis and emphysema. It is a progressive, fatal condition that
is one of the leading causes of death worldwide. The United States
Centers for Disease Control estimates that COPD costs the United States $36
billion dollars in direct and indirect costs.
Patients in the study who received at home non-invasive
ventilation in addition to oxygen therapy had a 51 percent
decreased risk of re-hospitalization or death, compared to those
who received oxygen therapy alone. (These results were based on a
hazard ratio of = 0.49, 95 percent confidence interval = (0.31,
0.77) p=0.002).
Patients who received home non-invasive ventilation at home went
a median of 4.3 months without dying or being admitted to the
hospital, compared to 1.4 months for those who did not receive
non-invasive ventilation.
"These study results add further weight to the existing evidence
supporting the broader use of non-invasive ventilation for patients
living with COPD. The results strengthen arguments for a pivotal
study in the area," said ResMed chief medical officer, Glenn Richards, M.D.
"In particular, the results are important because they show
giving patients with hypercapnic COPD a non-invasive ventilation
device for use in the home can very significantly cut their risk of
re-hospitalization and death after an acute worsening of the
disease."
"Today, nearly one in four patients with COPD in the United States will be re-hospitalized
following an acute exacerbation, significantly impacting patients'
quality of life and driving increased costs to healthcare systems
and payers," Dr Richards said.
To curb the financial impact of COPD, the U.S. Centers for
Medicare and Medicaid Services has started penalizing
hospitals that have high readmission rates after an acute
exacerbation of COPD.
"We hope these results will have a positive impact on current
practice and encourage more healthcare professionals to consider
the role of non-invasive ventilation in managing their COPD
patients," Dr Richards said.
More detail on the HOT HMV study can be found at
www.guysandstthomas.nhs.uk.
About COPD
COPD is a collection of lung diseases including chronic bronchitis
and emphysema. It is a progressive, fatal condition that causes
irreversible damage to the lungs and airway. It can have a major
impact on an individual's quality of life. It is one of the leading
causes of death worldwide and is the only major disease that is
increasing in prevalence globally, across all continents.
During the course of their disease, COPD patients can
experience acute exacerbations, which manifest themselves as a
sudden worsening of symptoms and can lead to respiratory failure,
hospitalization and death. Although the damage caused by COPD
cannot be reversed, it is possible to slow the progression of the
disease through treatment and lifestyle changes.
About The HOT-HMV Study
HOT-HMV is a multi-center randomized controlled trial conducted in
the United Kingdom that evaluated
the role of at home non-invasive ventilation in the treatment of
hypercapnic COPD. One hundred sixteen patients who
experienced an acute worsening of their COPD that required
hospitalization were randomized to receive at home non-invasive
ventilation plus oxygen therapy or to at home oxygen therapy
alone.
The primary endpoint was re-hospitalization free survival
defined as the time from trial intervention to either hospital
admission or death as measured over the course of one year.
Secondary outcome measures included measurements of lung function
and changes in health related quality of life.
About ResMed
ResMed (NYSE:RMD) changes lives with award-winning medical devices
and cutting-edge cloud-based software applications that better
diagnose, treat and manage sleep apnea, chronic obstructive
pulmonary disease (COPD) and other chronic diseases. ResMed is a
global leader in connected care, with more than 1 million patients
remotely monitored every day. Our 5,000-strong team is committed to
creating the world's best tech-driven medical device company –
improving quality of life, reducing the impact of chronic disease,
and saving healthcare costs in more than 100 countries.
ResMed.com | Facebook | Twitter | LinkedIn
Contacts:
|
|
For News
Media
|
For
Investors
|
Alison
Graves
|
Agnes Lee
|
Director, Corporate
Communications
|
Senior Director,
Investor Relations
|
O:
858-836-6789
|
O:
858-836-5971
|
news@resmed.com
|
investorrelations@resmed.com
|
Logo -
http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-study-shows-using-non-invasive-ventilation-therapy-to-treat-patients-with-chronic-obstructive-pulmonary-disorder-copd-at-home-significantly-reduces-risk-of-re-hospitalization-and-death-300322797.html
SOURCE ResMed Inc.